Stocks and Investing
Stocks and Investing
Mon, May 13, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, May 10, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Balaji Prasad Maintained (TARS) at Buy with Increased Target to $60 on, May 10th, 2024
Balaji Prasad of Barclays, Maintained "Tarsus Pharmaceuticals, Inc." (TARS) at Buy with Increased Target from $50 to $60 on, May 10th, 2024.
Balaji has made no other calls on TARS in the last 4 months.
There are 4 other peers that have a rating on TARS. Out of the 4 peers that are also analyzing TARS, 1 agrees with Balaji's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrea Tan of "Goldman Sachs" Maintained at Hold with Increased Target to $30 on, Thursday, February 29th, 2024
These are the ratings of the 3 analyists that currently disagree with Balaji
- Francois Brisebois of "Oppenheimer" Maintained at Buy with Increased Target to $61 on, Thursday, May 9th, 2024
- Anthony Petrone of "Jefferies" Maintained at Strong Buy with Increased Target to $44 on, Wednesday, March 6th, 2024
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $57 on, Wednesday, February 28th, 2024
Contributing Sources